proud I’m our XXXX. and afternoon. you, at incredibly accomplishments of Chris, good and Thank for our team Retrophin
of we to our Phase with successful of including X the in continue Specifically, launch and two our new and continue formulation commercialized new studies. to we products, sparsentan pivotal patients identify reach advance our through Thiola
disappointing for programs of under not included L-UDCA but program ending development declining made activities fosmetpantotenate, move exercise collaboration. study. further the to our for that to from and development It the the discontinuing the results criteria FORT also decisions prudent This includes advancement. following Censa our also We the option did our meet difficult, beyond
make actions company on position together key Notably, and rare that organization the and delivery priorities dedicated significant progress to in community. leading clear focus become patients disease will the to to these come innovation the of a believe our hope allowed global us to with a we
kidney Maximizing for highest remains patients our potential sparsentan’s with rare disorders priority.
For XX have the nephrology been clinical nephrology years, few, those that. in sparsentan, changing been in With we last nonexistent. too rare trials are nearly and the have
Our potential successful, trials approved underserved FSGS the treatment DUPLEX change and the the XXX,XXX to studies of the U.S. the rare impacting the patients living for that potential disorders as more than the they landmark have deliver first paradigm If prospect and Europe. currently and nephropathy. PROTECT IgA are to these medicine viewed have in and for
pivotal enrollment our studies seen why initiation. on focus quickly our high-quality maintaining is possible, the executing near-term is the of while This as we the since have of as conduct primary trials
line readouts pleased to I’m a result pivotal are will enrollment enable our our from reaching we as the solid our several the milestones team’s top on well months, operational over of execution clinical and to way last that report study. that
positive, of patient next the of to submit milestone this us top on two U.S. DUPLEX, filings approval months, first-half are anticipate the keeps We with regulatory year. the for track enrollment data next approaching analysis. And enable reaching our XXXth line and In proteinuria Europe. in XX-week in the to in we which the FSGS report if
in headway made PROTECT with We nephropathy. of Study pivotal IgA also our of substantial enrollment sparsentan
Study. the to learnings synergies our and for and awareness patients create a investigators from leveraged We DUPLEX growing enthusiasm have PROTECT and high Study among the
momentum XX-week confidence point, support inflection the next proteinuria enrollment the top data resulted year which both we positive year. in have you in in gives of we key this the forward studies reach and our great our enrollment later as line in We has to early look from us first-half milestones updating achieving XXXX. clearly target analysis This meaningful a for to of by
of potential help opportunities. continued additional also we’ve priority sparsentan’s to to part explore evaluate to maximize opportunities patients, our As development to
have mentioned preclinical we on As exploratory Alport previous our syndrome. call, in seen we encouraging work
team we progress on in to indication. evaluating to later pursue Our an this whether continues making clinical make decision additional a and feasibility, anticipate year
is Our our main upon teams’ priority alongside build to capabilities. commercial sparsentan’s strong advancement
products for focused that successful full we launch may a of of and are our on so prepare this, the approved We potential optimize sparsentan. ultimately
our and company commercial R&D our successful commercial I teams, have to of keeping respect who the rare with it execution foundation have most to patients families, journey. upon to understanding must and earning as of as addition clinical of are treatment the a where the them is patient what they on and In and deep disease must a well stage the A trust are, organization. continue be their built impressed their communities. important And
to has patients and therapies. continued organization deliver our life-changing is our new This identify how
our have to good continue how the and it successful as a a THIOLA needs We of to of listened patients. of launch serves example have we EC,
of new reduce number to of us and their manage tablets it patients of the potential two-thirds formulation, our ultimately Prior EC cystinuria necessary administration the the market, approximately introducing would provided patients. the product the because choose to that to told to potential for cystinuria market new research freedom
we that our to and needs within plan EC THIOLA those discontinued new reached a execute report who understand by reengaging have have patients, and six This to months ability I’m available, their identify to of launch mark. making previously that patients including to demonstrates therapy. pleased
robust sparsentan, that approved, be able launch we that for will we degree to and high if potential to Additionally, maximize its patients. foundation gives it a have a confidence us nephrology in of
CHOLBAM, to where our their disorders Zellweger execution manage from goal Spectrum We with acid also disease have to patients liver continue or is help solid synthesis bile Disorders.
to clinical NDA that may to Chenodal lead a and specialists, including hepatologists and that rare talk geneticists continues CTX. grow, shortly. to patients with Noah more recently resulting ultra are label the an also identification initiated new support treatment efforts and these ultimately in bit Our pediatric for of will we with conditions. a development about
business diversify to growth opportunities development. evaluate potential through to is our priority final Our
We continue to ultra and the rare opportunistically look rare within spaces.
we we remain will can believe on expertise create current to transactions, act leverage our only to where disciplined value. Importantly, meaningful we
over Noah turn me update. for the clinical Let to call Noah? now
